Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3214062 | 0.85 | MAPK14 (0.54) | HPGDALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL22573829 | 0.74 | ADORA2A (0.64) | ALDH1A1EGLN1 | |
| SCHEMBL17581163 | 0.72 | HPGD (0.52) | HPGDALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL17610472 | 0.71 | GALR3 (0.53) | HPGDCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3263497 | 0.71 | POLB (0.63) | HPGDALDH1A1POLBL3MBTL1CYP1A2 | |
| SCHEMBL921981 | 0.69 | HPGD (0.70) | HPGDALDH1A1POLBSMN1; SMN2LMNA | |
| SCHEMBL2430797 | 0.68 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1 | |
| SCHEMBL2430799 | 0.68 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1 | |
| SCHEMBL1417227 | 0.68 | MAPK14 (0.61) | SMN1; SMN2MAPK14MAPK11NPC1RAB9A | |
| SCHEMBL1012283 | 0.68 | TYRO3 (0.54) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | claimed |
| EP-1687284-B1 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-29 | — | — | EP | claimed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | claimed |
| EP-1687284-A2 | p-38 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2005012241-A2 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-10 | — | — | WO | claimed |
| US-20050020590-A1 | P-38 kinase inhibitors | NOVARTIS AG (CH) | 2005-01-27 | — | — | US | claimed |
| EP-2251333-A1 | Biphenyl derivatives as P-38 kinase inhibitors | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| EP-1990338-B1 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7700622-B2 | p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| EP-1990338-A2 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1687284-B1 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1687284-A2 | p-38 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005012241-A2 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-10 | — | — | WO | disclosed |
| US-20050020590-A1 | P-38 kinase inhibitors | NOVARTIS AG (CH) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111999-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | DRD4 4847/4885HSP90AA1 77/4885HSP90AB1 60/4885 |
| US-20050020590-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | DRD4 4852/4885HSP90AA1 79/4885HSP90AB1 52/4885 |
| US-20100234404-A1 | P-38 Kinase Inhibitors | MAPK8, MAP3K8, MAPK1 | DRD4 4847/4885HSP90AA1 77/4885HSP90AB1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.